Abstract
Immunoglobulin E (IgE) plays a central role in the development of allergic diseases. In sensitized individuals, IgE antibodies bind to receptors on mast cell and basophil surfaces, releasing preformed and newly generated mediators that initiate an immunologic cascade and inflammatory symptoms. Omalizumab (Xolair®) is a humanized monoclonal antibody designed to bind specifically to IgE. It was approved by the United States Food and Drug Administration in 2003 for the treatment of patients with moderate-to-severe persistent asthma that is inadequately controlled with inhaled corticosteroids (ICS) and who have a positive skin test or in vitro reactivity to a perennial aeroallergen. In clinical trials in such patients, omalizumab reduced the incidence of asthma exacerbations, severe exacerbations, the use of rescue medication, and improved both symptoms and quality of life (QOL).
Keywords: IgE, allergy, asthma, rhinitis, omalizumab
Current Pharmaceutical Design
Title: IgE, Allergic Diseases, and Omalizumab
Volume: 12 Issue: 30
Author(s): L. M. DuBuske
Affiliation:
Keywords: IgE, allergy, asthma, rhinitis, omalizumab
Abstract: Immunoglobulin E (IgE) plays a central role in the development of allergic diseases. In sensitized individuals, IgE antibodies bind to receptors on mast cell and basophil surfaces, releasing preformed and newly generated mediators that initiate an immunologic cascade and inflammatory symptoms. Omalizumab (Xolair®) is a humanized monoclonal antibody designed to bind specifically to IgE. It was approved by the United States Food and Drug Administration in 2003 for the treatment of patients with moderate-to-severe persistent asthma that is inadequately controlled with inhaled corticosteroids (ICS) and who have a positive skin test or in vitro reactivity to a perennial aeroallergen. In clinical trials in such patients, omalizumab reduced the incidence of asthma exacerbations, severe exacerbations, the use of rescue medication, and improved both symptoms and quality of life (QOL).
Export Options
About this article
Cite this article as:
DuBuske L. M., IgE, Allergic Diseases, and Omalizumab, Current Pharmaceutical Design 2006; 12 (30) . https://dx.doi.org/10.2174/138161206778559641
DOI https://dx.doi.org/10.2174/138161206778559641 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel and Current Treatment Concepts Using Pulmonary Drug Delivery
Current Pharmaceutical Design A Review of Fish Lectins
Current Protein & Peptide Science The Potential of Ellagic Acid as a Possible Antimalarial Drug Candidate
Current Bioactive Compounds Complementary and Alternative Medical Therapies in Fibromyalgia
Current Pharmaceutical Design From Hygiene Hypothesis to Novel Allergic Asthma Therapeutics
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Nanoceuticals as an Emerging Field: Current Status and Future Prospective
Current Nutrition & Food Science An Alternative Method for the Synthesis of Tetraketones and their Lipoxygenase Inhibiting and Antioxidant Properties
Letters in Drug Design & Discovery Microvascular Theory of Exercise-Induced Bronchoconstriction in Asthma: Potential Implication of Vascular Endothelial Growth Factor
Inflammation & Allergy - Drug Targets (Discontinued) Investigation into the Formation Mechanism and Distribution Characteristics of Suspended Microparticles in MQL Grinding
Recent Patents on Mechanical Engineering Biomarkers Obtained by Non-Invasive Methods in Patients with COPD: Where do we Stand, what do we Expect?
Current Medicinal Chemistry Flavonoids on Allergy
Current Pharmaceutical Design Reciprocity in Microbiome and Immune System Interactions and its Implications in Disease and Health
Inflammation & Allergy - Drug Targets (Discontinued) Double Point Modified Analogs of Vitamin D as Potent Activators of Vitamin D Receptor
Current Pharmaceutical Design New Insights into Invasive Aspergillosis - from the Pathogen to the Disease
Current Pharmaceutical Design Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Complex Effect of Adenovirus Early Region Proteins on Innate Immune System
Inflammation & Allergy - Drug Targets (Discontinued) Genetic Mapping of Pharmacogenetic Regulatory Variation
Current Pharmaceutical Design Drug Acyl Glucuronides: Reactivity and Analytical Implication
Current Pharmaceutical Analysis Seminal Fluid Hypersensitivity: A Case Report and Review of the Literature
Current Women`s Health Reviews Critical Steps in Tissue Processing in Histopathology
Recent Patents on DNA & Gene Sequences